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Thalidomide’s reported ability to inhibit angiogenesis has led to clinical trials determining its eﬀectiveness in combating various
types of cancer. This study explored thalidomide’s antitumorigenic potential when administered alone and in combination with
cisplatin to DBA2/J mice whose tumors were induced by murine erythroleukemic cells. Thalidomide treatment alone produced no
signiﬁcant inhibitory eﬀect on tumor development and metastasis. Mice that received both drugs had signiﬁcantly lower incidences
of both primary and secondary tumors as compared to the untreated control group. Cisplatin, administered alone or in combina-
tion with thalidomide, led to a signiﬁcant delay in tumor formation and a longer life span than was recorded in untreated mice.
However, the combination treatment results were not signiﬁcantly diﬀerent from those of cisplatin treatment used as a single agent.
In in vitro cell multiplication studies using murine erythroleukemic and murine endothelial cells, thalidomide failed to inhibit cell
proliferation. However, cisplatin treatment with or without thalidomide, signiﬁcantly inhibited the multiplication of both cell lines
in a dose dependent manner. Thalidomide does not appear to be a beneﬁcial adjuvant to cisplatin treatment.
INTRODUCTION
One of the most promising areas of cancer research,
which was proposed by Dr Judah Folkman in 1971, involves
inhibition of blood vessel growth, called angiogenesis [1].
Thalidomide, an antiangiogenic agent currently in clinical
trials for an assortment of cancer treatments, was originally
prescribed as a sedative in Europe in the 1950s [2]. Due to
its apparent safety, the chemical was prescribed to pregnant
women to relieve morning sickness. Concerns surfaced when
some patients complained of tingling in their extremities
characteristic of peripheral neuropathy, and thalidomide was
laterbannedfromthemarketwhenitwasassociatedwiththe
inﬂux of newborns aﬄicted with phocomelia, a birth defect
characterized by stunted limb formation [3].
Studies to identify thalidomide’s teratogenic mecha-
nism led to the discovery of its anti-inﬂammatory and im-
munomodulatory actions by facilitating the degradation of
tumor necrosis factor-alpha (TNF-α)m R N Ai nm o n o c y t e s
[3]. In 1998, the US Food and Drug Administration (FDA)
approved marketing of thalidomide for treatment of ery-
thema nodosum leprosum (ENL), an inﬂammatory condi-
tion associated with lepromatous leprosy [4]. The Celgene
Corporation (Warren, NJ, USA) is the only producer of
Thalomid, the commercially available form of thalidomide.
Thalomid is also available oﬀ-label to combat a variety of
dermatologicalconditions,complicationsofhumanimmun-
odeﬁciency virus (HIV) infection, Crohn’s disease, ulcers of
the mouth and pharynx, chronic graft-versus-host disease,
and rheumatoid arthritis [5].
Exploration for thalidomide’s mechanism of teratogenic-
ity has continued and Kenyon et al demonstrated that it
is unrelated to the TNF-α mRNA degradation mentioned
earlier [6]. Although its role in teratogenesis is not fully de-
ﬁned, thalidomide’s ability to inhibit bFGF and VEGF in-
duced angiogenesis in areas other than fetal tissue has been
documented. When thalidomide’s antiangiogenic capabili-
ties were applied to cancer research in rodent models, con-
ﬂicting results were obtained [7, 8, 9]. Despite the lack of
conclusive results in murine models, thalidomide entered
humanclinicaltrialswhereinconsistentanddiscouragingre-
sults were produced as well. Thus far, thalidomide has been
mostpromisingintreatingmultiplemyeloma,acancerofthe
bone marrow. Due to the perplexing results of thalidomide
treatment as a single agent, the focus of thalidomide research
has shifted to exploring this drug’s antitumorigenic abilities
as an adjuvant to chemotherapy.
The eﬃcacy of cis-dichlorodiammineplatinum (II), mar-
keted as cisplatin, has been thoroughly studied since its in-
troduction to cancer therapy [10]. Cisplatin has proved to
be eﬀective against solid tumors of the cervix, bladder, and
prostate [11]. The cytotoxicity of cisplatin lies in its abil-
ity to form interstrand and intrastrand cross-links in DNA
[10]. Prior studies have demonstrated that cisplatin is toxic
to murine erythroleukemic cells (MEL), including the GM-
86 cell line, and cisplatin has also been identiﬁed as antimi-
crobial, immunosuppressive, and mutagenic [12, 13, 14].
The purpose of this study is to evaluate the antitumori-
genic activity of thalidomide, when used alone and in com-
bination with cisplatin in DBA2/J mice whose solid tumors
were induced by a subcutaneous injection of GM-86 MEL
cells. The study documents primary tumor incidence, sec-
ondary tumor incidence, day of tumor detection, life span,
tumor volume, and spleen enlargement. To further elucidate8 J. M. B. Ruddy and S. K. Majumdar 2:1 (2002)
the eﬀects of this combination drug treatment, in vitro stud-
ieswereconductedutilizingtheGM-86Friendvirus-induced
murine erythroleukemic cell line and the SVEC4-10 murine
lymph node endothelial cell line.
MATERIALS AND METHODS
Cellmaintenance
Murine erythroleukemic cells have previously been
shown to induce solid tumor formation at the site of a
subcutaneous injection of cells [15]. These cells were de-
rived from virally transformed erythroblasts, grow in sus-
pension, and were purchased from the Coriell Institute for
Medical Research’s Cell Repository (Camden, NJ, USA). The
c e l l sw e r ec u l t u r e di nD u l b e c c o ’ sM o d i ﬁ e dE a g l e ’ sM e d i u m
(Gibco BRL, Rockville, Md, USA) supplemented with 10%
fetal calf serum (DME-10) and kept in a 37◦C incubator with
7.5% CO2 in air.
The SVEC4-10 murine lymph node endothelial cell line
is SV-40 transformed into a continuous cell line, but main-
tains the morphological and functional characteristics of
normal endothelial cells [16]. These cells were purchased
fromtheAmericanTissueCultureCollection(Rockville,Md,
USA), grew as monolayer ﬁbroblasts, and were cultured in
the same conditions as stated above.
Drugpreparation
Thalidomide (α-phthalimidoglutarimide; supplied in
gratis by the Celgene Corporation, Warren, NJ, USA) is a
water-insoluble white powder and was suspended in phos-
phate buﬀered saline (PBS) to a concentration of 1µg/µlf o r
theinvitrostudies.Thissolutionwasstoredat4◦C.Inthetu-
mor development study, thalidomide was prepared on each
treatment day. It was ﬁrst emulsiﬁed in .1ml Tween-80 and
then suspended in PBS to reach a ﬁnal concentration such
that an injection of 0.2ml would deliver 400mg/kg, depend-
ing on the weight of the mice.
Cisplatin (Sigma-Aldrich, St Louis, Mo, USA) was dis-
solved in dimethyl sulfoxide (DMSO) and diluted in sterile
w a t e rt oac o n c e n t r a t i o no f1µg/µl. This solution was kept
at 4◦C. No experimental culture contained more than 0.01%
DMSO. To be administered in the in vivo study, cisplatin was
dissolved in sterile water to a concentration of 1µg/µla n d
again stored at 4◦C. Each treatment day, this stock solution
was diluted in PBS so that an injection of 0.2ml delivered
2.5mg/kg or1.5mg/kg. Again, this calculation was depen-
dent on the weight of the mice.
Mousemaintenance
Four-week-oldfemaleDBA2/Jmicewerepurchasedfrom
the Jackson Laboratory (Bar Harbor, Me, USA), housed six
or seven to a cage, fed ad libitum, and observed daily. The
cages were changed twice per week and the mice were kept
in a climate-controlled room. Approval for this study was at-
tained from the Lafayette College Institutional Animal Care
and Use Committee (IACUC) and mice were handled ac-
cording to those guidelines.
Tumordevelopmentstudy
Seven-week-old female DBA2/J mice received a subcuta-
neous injection of 104 GM-86 MEL cells on the right hind
leg. The cell injection day was considered day zero. Drugs
were administered via intraperitoneal injections with a 25-
gauge syringe. Thalidomide treatment was 400mg/kg every
48hours beginning on day one and continuing for 15 doses
(n = 16). Cisplatin was administered at a concentration of
1.5mg/kg on day one, and cisplatin every 4days for a total of
4d o s e s( n = 12). The combination treated group received
both thalidomide and cisplatin in the manners explained
above (n = 15). The untreated control group was adminis-
t e r e db o t hd r u gs o l v e n t so nt h es a m ed a ya sd r u gt r e a t m e n t
(n = 18).
The mice were weighed once a week throughout the trial.
Thedayoftumordetectionwasrecordedandthedimensions
of the tumors were measured every 48hours. Tumor volume
was calculated in accordance with a similar study performed
by Kotoh et al [7] with the equation
tumor volume = length × width
2 × 0.5. (1)
Since life span was one of the parameters considered in the
study, the mice were brought to survival approximately 2–
3d a y sb e f o r et h e i rn a t u r a ld e a t h .T h em i c ew e r es a c r i ﬁ c e d
by cervical dislocation and the primary tumors, spleens, and
secondary tumors, if present, were excised and ﬁxed in 10%
phosphate buﬀered formalin. The size of the spleen was also
recorded at this time. The tumor development study lasted
51days.
GM-86MELcellmultiplicationstudy
The cell multiplication study was conducted as described
in Ruddy et al [17]. GM-86 MEL cells were seeded in 25cm2
ﬂasks at 105 cells/ml in 6ml of DME-10 and treated with
thalidomide (0, 30, 50, or 100 µg/ml; n = 7), cisplatin (0, 0.1,
0.5, or 1.0µg/ml; n = 6), both (100µg/ml thalidomide + 0.1,
0.5, or 1.0µg/ml cisplatin; n = 6), or neither. The number
of viablecells/ml was counted by the Trypan blue exclusion
method every 24hours for 5days [18].
SVEC4-10murineendothelialcellmultiplicationstudy
Six-well plates were seeded with 5 × 104 SVEC4-10
cells/well in 4ml of DME-10, where the surface of each well
was nearly 10cm2. These cells received the same drug treat-
ments as stated above (n = 6, where 2 wells composed one
replicate). Because these cells grow by adhering to their sub-
strate, 0.25% buﬀered trypsin (Gibco BRL, Rockville, Md,
USA) was used to loosen the cells from the wells for count-
ing by the Trypan blue exclusion method every 24hours for
4days.
Statisticalanalysis
The Prism GraphPad program was used to calculate the
Student t test (P<. 01) and 2-way Analysis of Variance
(ANOVA) (P<. 01) [19]. The χ2 and Fisher exact test were
also utilized [20].2:1 (2002) Thalidomide on Mouse Tumor Development 9
Table 1. Results of the tumor development study wherein DBA2/J mice received thalidomide, cisplatin, both drugs, or neither.
Primary tumor
incidence (%)
Mean tumor
detection day
±1S E M
Mean life span
±1S E M
Secondary tumor
incidence (%)
Mean tumor
volume (mm3)
at death
±1S E M
Incidence
of spleen
enlargement
(%)
Untreated
control
17/18
(94.4%)
13.7 ± 0.5
n = 17
42.4 ± 1.6
n = 17
12/17
(70.59%)
8593.7 ± 1207.2
n = 16
9/17
(52.94%)
Thalidomide 13/16
(81.25%)
15.7 ± 1.9
n = 13
38.9 ± 1.7
n = 13
6/13
(46.15%)
9624.2 ± 1086.0
n = 13
10/13
(76.92%)
Cisplatin 9/12
(75.0%)
22.5 ± 3.3†
n = 8
46.8 ± 1.5‡
n = 9
5/9
(55.56%)
7925.8 ± 1773.9
n = 8
7/9
(77.78%)
Thalidomide
+ cisplatin
9/15∗
(60%)
27.56 ± 3.2†‡
n = 9
45.8 ± 1.5‡
n = 9
2/9∗
(22.22%)
7305.9 ± 1431.9
n = 9
4/9
(44.44%)
∗ statistical diﬀerence from the untreated control group (P ≤ .05), as determined by the χ2 and Fisher exact test.
† statistical diﬀerence from the untreated control group (P ≤ .01), as determined by the Student t test.
‡ statistical diﬀerence from the thalidomide treated group (P ≤ .01), as determined by the Student t test.
RESULTS
Tumordevelopmentstudy
The results of the tumor development study are summa-
rized in Table 1. The only signiﬁcant inhibition of primary
or secondary tumor incidence was seen in the combination
treated group, as determined by the χ2 and Fisher exact test.
When compared to the untreated control, both cisplatin and
combination treatment produced a signiﬁcant delay in tu-
mor formation, according to the Student t test. Mice that re-
ceived combination treatment also remained tumor-free sig-
niﬁcantly longer than those treated with only thalidomide,
but no statistical diﬀerence was found between the cisplatin
and combination treated mice.
The determination of mean life spans of mice in the tu-
mor development was limited by the fact that the study was
terminated at 51days. Mice were sacriﬁced approximately 2–
3days from natural death via cervical dislocation, when they
showed matting and thinning of the fur, a substantial tu-
mor burden, and an overall lethargy. These parameters were
constant across all treatment groups. The Student t test de-
termined that cisplatin treatment, both alone and in com-
bination with thalidomide, signiﬁcantly increased the life
span of tumor-aﬄicted mice beyond that of the thalidomide
treated mice. The diﬀerence between cisplatin and combina-
tion treatment was negligible, however.
The tumor development patterns of each treatment reg-
imen is shown in Figure 1.T h en v a l u e sa b o v ee a c hb a rr e p -
resent the number of mice alive and aﬄicted with tumors
at that point. The large increases in tumor volume between
time points were observed among the four treatment groups.
The signiﬁcantly delayed tumor development of cisplatin
and combination treated groups caused the tumor growth in
these two groups to be oﬀset from that of the untreated con-
trolandthalidomidetreatedmicebyabout1week.Thisisev-
idenced in the peak tumor volumes of the latter two groups
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Figure 1. Mean tumor value ( control, thalidomide, cisplatin,
and combination)at20,27,35,and42dayssincetumorcellinoculation.
The n values vary depending on the number of surviving mice aﬄicted with
a tumor on that day. Bars represent ±1S E M .
occurring on day 35, whereas the same climax was reached
at day 42 by the combination treated mice. Upon death, the
mean tumor volume was calculated for each treatment regi-
men, however, no statistical diﬀerence was detected between
any treatment groups, according to the Student t test (data
not shown).10 J. M. B. Ruddy and S. K. Majumdar 2:1 (2002)
The GM-86 MEL cell line was derived from mouse ery-
throblasts transformed by the Friend virus, a retrovirus
known to cause splenomegaly in mice. The incidence of this
spleen enlargement was documented to determine if any
treatment had a therapeutic eﬀect. The spleen was consid-
ered enlarged when it was approximately three times the size
of a normal, healthy spleen. No clear trend can be discerned
from the percentage of mice exhibiting spleen enlargement
and none of the treatments diﬀered signiﬁcantly from the
untreatedcontrolwhenanalyzedthroughχ2 andFisherexact
tests (data not shown).
GM-86MELcellmultiplicationstudy
TheGM-86MELcellmultiplicationdataarepresentedas
percentages of the control. 2-way ANOVA failed to ﬁnd a sta-
tistically signiﬁcant eﬀect of the thalidomide treatment (see
Figure 2a) on cell multiplication. Conversely, cisplatin treat-
ment alone (see Figure 2b) and in combination with thalido-
mide (see Figure 2c) inhibited cell proliferation in a time and
dose dependent manner. Additionally, statistical analysis of
cisplatin treated versus combination treated cells indicated
that the incorporation of thalidomide in the drug treatment
strengthened the inhibitory eﬀect on GM-86 MEL cell mul-
tiplication over the ﬁrst 48 to 72hours.
SVEC4-10murineendothelialcellmultiplicationstudy
When SVEC4-10 cells received treatment with thalido-
mide (see Figure 3a), again, no statistically signiﬁcant result
was observed. Just as in the GM-86 MEL cell multiplication
study, both cisplatin (see Figure 3b) and combination (see
Figure 3c)drugtreatmentregimensresultedintimeanddose
dependent inhibition of cell multiplication, according to 2-
way ANOVA. Contrary to the relationship noted above, over
the ﬁrst 48 to 72hours, statistical analysis indicated that cis-
platin alone displayed a stronger inhibitory eﬀect than com-
bination treatment on the SVEC4-10 cells.
DISCUSSION
The concept of supplementing chemotherapy with an-
tiangiogenic agents is aimed at improving the eﬀect of
chemotherapy without increasing the toxicity to the patient
[21]. Reducing or stabilizing the vasculature of a tumor
would cause the death of the cells farthest from capillaries,
ultimately leading to a decreased tumor mass and an in-
creased eﬃciency of administered chemotherapy drugs [21].
The angiogenesis inhibitors could also prevent regrowth and
progression to metastatic disease after a chemotherapeutic
regimen [21]. Unsuccessful studies utilizing thalidomide as
a single agent in both mice and humans have recommended
that future research be done to evaluate its eﬃcacy as an ad-
juvant to chemotherapy [22, 23].
This study has documented the inability of thalidomide
to inhibit solid tumor growth and metastasis when admin-
istered as a single agent to DBA2/J mice whose solid tumors
were induced with GM-86 MEL cells. Previous studies uti-
lizing murine breast cancer [22], melanoma [24], and colon
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Figure 2. GM-86 cell multiplication after treatment with (a) thalidomide
( 100µg/ml,  50µg/ml, and  30µg/ml); (b) cisplatin ( 1.0µg/ml, 
0.5µg/ml, and  0.1µg/ml); (c) both 100µg/ml thalidomide and either 0.1
(), 0.5 (), or 1.0 ()µg/ml cisplatin. Bars represent ±1S E M .2:1 (2002) Thalidomide on Mouse Tumor Development 11
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Figure 3. CVEC4-10 cell multiplication after treatment with (a) thalido-
mide (100µg/ml, 50µg/ml, and 30µg/ml); (b) cisplatin (1.0µg/ml,
 0.5µg/ml, and  0.1µg/ml); (c) both 100µg/ml thalidomide and either
0.1 (), 0.5 (), or 1.0 ()µg/ml cisplatin. Bars represent ±1S E M .
cancer [25] models recorded similar results. When murine
breast cancer was treated with thalidomide and chemother-
apy drugs, reduced primary and secondary tumor growth
were recorded [22]. The eﬀect of combination treatment
with thalidomide and cisplatin on solid tumors induced by
GM-86 MEL cells was signiﬁcantly better than thalidomide
alone,butnostatisticalanalysishasshowncombinationther-
apy to be more beneﬁcial than therapy with cisplatin as a sin-
gle agent.
A previous study, which withheld treatment until tumor
formation, reported that combination therapy with thalido-
mide and a chemotherapeutic agent was most eﬀective when
initiated before the tumor volume reached 50mm3 [22].
Since this study began treatment 24hours after cell inocu-
lation, the drugs had the opportunity not only to slow tumor
growth, but also to prevent it completely. The in vitro results
of GM-86 MEL cells exposed to combination treatment with
thalidomide and cisplatin showed an increased toxic eﬀect
over cisplatin alone. It, therefore, appears that the signiﬁcant
reduction in primary tumor incidence and increased delay
before tumor formation seen in the combination group can
be attributed to the death of some GM-86 MEL cells in the
initial inoculation.
While controlling primary tumor volume is vital, the ul-
timate goal is to prevent metastasis. Nguyen et al, observed
that once a tumor had reached 1000mm3, it established a
vascular system that allowed rapid tumor growth and pro-
gression to metastatic disease [22]. A similar growth pat-
tern was documented in this study. While initial develop-
ment may have been delayed, tumors of the cisplatin and
combination treated groups were equivalent in volume to
those of the untreated control and thalidomide treated mice
at the time of death; but signiﬁcantly more mice of the lat-
ter two groups were harboring secondary tumors. Perhaps,
the decreased life spans of mice in the untreated control and
thalidomide treated groups can be attributed more to the
progression of metastatic disease than the volume of the pri-
mary tumors. Applying the cancer attacking strategies stated
by Teicher et al, the chemotherapeutic treatment apparently
lessened the cell load; and continued treatment with the an-
tiangiogenic agent may have slowed the regrowth and metas-
tasis such that the life span was increased [21].
Previous studies, which reported advantages to combi-
nation therapy with chemotherapeutic drugs and antiangio-
genic agents, did not quantify mice life spans [21, 22]. Be-
cause the majority of cancer treatments involve reducing tu-
mor volume, prolonging life, and increasing quality of life,
the ability of treatment regimens to increase life spans is im-
portant. Because the life spans of mice in combination treat-
ment were not signiﬁcantly longer than those of the cisplatin
treated mice, there is no clear evidence that thalidomide is an
eﬀective adjuvant to cisplatin therapy.
Thalidomide’s marked reduction in eﬃcacy when used
in mouse and rat models has been documented many times
and referred to earlier in this paper. While continued in vivo
studies may discover a particularly advantageous treatment
regimen, elucidation of thalidomide’s mechanism of action
in human versus rodent systems will be achieved through12 J. M. B. Ruddy and S. K. Majumdar 2:1 (2002)
in vitro studies. The primary goal of many culture investiga-
tions is to ﬁnd a system in which thalidomide is eﬀective, to
isolate the active agent, and then synthesize derivatives that
lack thalidomide’s teratogenicity and other adverse eﬀects.
This study appears to be the ﬁrst one reporting specif-
ically on the eﬀect of thalidomide treatment of cultured
murine endothelial cells and has documented no inhibition
of cell proliferation. A previous study has documented that
thalidomide had no eﬀect on human aortic endothelial cell
proliferation [26]. In a contrasting investigation, however,
thalidomide did inhibit the proliferation of human umbili-
cal vein endothelial cells in a dose dependent manner [27].
In terms of the cancerous GM-86 MEL cell line, again no
inhibitory eﬀect on cell proliferation resulted from thalido-
mide treatment. In vitro studies on human glioma [27],
Ehrlich ascites tumor [28], and human prostate carcinoma
cells [26] support this notion that thalidomide is not cy-
totoxic to cancer cells. Studies have suggested that thalido-
mide is metabolized by the cytochrome P450 isozyme [29].
In a recent study the agent was found not to increase or de-
crease signiﬁcantly the proliferation of cultured human and
murine cells in the presence or absence of human liver S9
fraction [30].
Thalidomide is reported to be an angiogenesis inhibitor;
however, the exploration of this role in tumor development
was not part of the present study. When administered as a
single agent, thalidomide failed to inhibit tumorigenesis and
metastasis in DBA2/J mice whose tumors were induced by
GM-86 MEL cells. In consideration of thalidomide’s poten-
tial as an adjuvant to chemotherapy, this investigation docu-
mented no advantage to combination therapy beyond that of
cisplatin treatment alone. Whether thalidomide’s lack of ef-
ﬁcacy is indicative of its inability to prevent angiogenesis or
the absence of the proper metabolism is an area for further
study.
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